Ignite Creation Date:
2024-05-05 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00419835
Status:
COMPLETED
Last Update Posted:
2011-08-04
First Post:
2007-01-08
Brief Title:
Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy a Clinical Trial on Type 2 Diabetes Mellitus
Sponsor:
University of Sao Paulo
Organization:
University of Sao Paulo
Study Overview
Official Title:
Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy a Clinical Trial on Type 2 Diabetes Mellitus
Status:
COMPLETED
Status Verified Date:
2007-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Chronic kidney disease CKDhas become a significant health problem worldwide Strategies to decrease the rate of progression of this disease and reduce the number of patients needing dialysis or renal transplantation are urgently needed In this study we wish to compare the effect of dual blockade of renin-angiotensin system ACE inhibitors plus angiotensin II receptor blocker compared to the effect of ACE inhibitor monotherapy in patients with diabetic chronic nephropathy
Detailed Description:
Diabetic kidney disease is the current leading cause of chronic kidney disease CKD in the world Despite all efforts to control this disease rates of CKD progression are still high and a significant number of patients will ultimately need renal replacement therapy Pharmacological blockade of renin-angiotensin system is one of the key elements of CKD secondary prevention and ACE inhibitors or angiotensin II receptor 1 blocker ARBcan be used for this purpose However it is still not clear if dual blockade ACEi and ARBs simultaneouslyis superior to monotherapy with ACE inhibitors or ARBs A recent trial has suggested that dual blockade is superior to monotherapy in non-diabetic chronic kidney disease The purpose of this trial is to evaluate the effect of combination therapy compared to ACE inhibitors alone in type 2 diabetic patients with macroalbuminuric diabetic nephropathy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None